Fludarabine, Cyclophosphamide, and Multiple-Dose Rituximab as Frontline Therapy for Chronic Lymphocytic Leukemia

BACKGROUND: Fludarabine, cyclophosphamide and rituximab (FCR) results in durable responses in patients with previously untreated chronic lymphocytic leukemia (CLL). Previous reports suggest that in patients with relapsed CLL a dose-intensified rituximab regimen increases response rates compared to s...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer
मुख्य लेखकों: Short, Nicholas J., Keating, Michael J., Wierda, William G., Faderl, Stefan, Ferrajoli, Alessandra, Estrov, Zeev, Smith, Susan C., O'Brien, Susan M.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2015
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4824541/
https://ncbi.nlm.nih.gov/pubmed/26218678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29605
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन